Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(93)
•••
Comment by MasterAlgaeon Sep 25, 2020 8:31am
224 Views
Post# 31619078

RE:New Coverage?

RE:New Coverage?
Antibe Therapeutics initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated coverage of Antibe Therapeutics with a Buy rating and C$1 price target. The analyst notes that the company's lead product Otenaproxesul - being developed to treat osteoarthritis of the knee - has a "significant opportunity" as a better NSAID and could also target the chronic pain market. McCarthy adds that the last two NSAIDs that went for reduced gastrointestinal issues generated $1B in first-year sales.

Read more at:
https://thefly.com/n.php?id=3165278
It came out yesterday morning:
Maxim analyst Jason McCarthy

Read more at:
https://thefly.com/n.php?id=3165278

https://thefly.com/landingPageNews.php?id=3165278&headline=ATBPF-Antibe-Therapeutics-initiated-with-a-Buy-at-Maxim
Antibe Therapeutics initiated with a Buy at Maxim Maxim analyst Jason McCarthy initiated coverage of Antibe Therapeutics with a Buy rating and C$1 price target. The analyst notes that the company's lead product Otenaproxesul - being developed to treat osteoarthritis of the knee - has a "significant opportunity" as a better NSAID and could also target the chronic pain market. McCarthy adds that the last two NSAIDs that went for reduced gastrointestinal issues generated $1B in first-year sales.

Read more at:
https://thefly.com/n.php?id=3165278
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities